Sofinnova Investments’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Sofinnova Investments’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,211,641	Closed	-$24.3M	–	81
2023 Q3	$24.3M	Buy	1,211,641 +383,636	+46%	+$9.74M	1.53%	21
2023 Q2	$23.4M	Sell	828,005 -611,057	-42%	-$14.7M	1.53%	19
2023 Q1	$24.8M	Buy	1,439,062 +435,017	+43%	+$8.81M	1.58%	17
2022 Q4	$20.2M	Buy	1,004,045 +420,688	+72%	+$9.05M	1.2%	21
2022 Q3	$12.6M	Buy	583,357 +254,960	+78%	+$6.97M	0.74%	27
2022 Q2	$9.23M	Buy	+328,397	New	+$8.7M	0.77%	29

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sofinnova Investments's ZNTL Position: Q4 2023 in Review

Sofinnova Investments sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 1,211,641 shares — an estimated $24.3M sold.

Sofinnova Investments first reported a position in ZNTL in Q2 2022 and held it in 6 quarters. The position peaked at $24.8M in Q1 2023. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

Sofinnova Investments reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Sofinnova Investments sold 1,211,641 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $24.3M.
Sofinnova Investments first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 6 quarters.
Sofinnova Investments's Zentalis Pharmaceuticals position peaked at $24.8M in Q1 2023.
120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on Sofinnova Investments's 13F filing for Q4 2023, filed 13 Feb 2024.